Prenatal omega-3 LCPUFA and symptoms of allergic disease and sensitization throughout early childhood - 2018
– a longitudinal analysis of long-term follow-up of a randomized controlled trial
World Allergy Organization Journal 201811:10, https://doi.org/10.1186/s40413-018-0190-7
K. P. Best, T. R. Sullivan, D. J. Palmer, M. Gold, J. Martin, D. Kennedy and M. Makrides
Increasing Omega-3 is good,
but, as has been known for decades, decreasing the Omega-6/Omega-3 ratio is better.
The Omega-3 index is the best measure – which essentially incorporates the O-6/O-3 ratio
Giving Omega-3 to the children would also help
- Allergy - Overview
- Food allergies in children may be due to earlier low Vitamin D, Omega-3 and Zinc – Aug 2017
- Increasing amount of omega-3 in mother’s milk resulted in fewer infant allergies – March 2016
- Overview: Omega-3 many benefits include helping vitamin D
- Omega-3 – fewer than 5 percent of adult women get the RDA – April 2018
- Asthma reduced 31 percent when Omega-3 taken during pregnancy – RCT Dec 2016
- Pregnancy and infants healthier with Omega-3 supplementation - many studies
- Omega-3 is vital for health, mail-in test is low cost and accurate
Download the PDF from VitaminDWiki
Background
Randomized controlled trials of prenatal omega (ω-3) long chain polyunsaturated fatty acid (LCPUFA) supplementation are suggestive of some protective effects on allergic sensitization and symptoms of allergic disease in childhood. Due to the nature of the atopic march, investigation of any effects of this prenatal intervention may be most informative when consistently assessed longitudinally during childhood.
Methods
Follow-up of children (n = 706) with familial risk of allergy from the Docosahexaenoic Acid to Optimize Mother Infant Outcome (DOMInO) trial. The intervention group received fish oil capsules (900 mg of ω-3 LCPUFA) daily from <21 weeks’ gestation until birth; the control group received vegetable oil capsules without ω-3 LCPUFA. This new longitudinal analysis reports previously unpublished data collected at 1 and 3 years of age. The allergic disease symptom data at 1, 3 and 6 years of age were consistently reported by parents using the "International Study of Asthma and Allergies in Childhood" (ISAAC) questionnaire. Sensitization was determined by skin prick test to age specific, common allergen extracts.
Results
Changes over time in symptoms of allergic disease with sensitization (IgE-mediated) and sensitization did not differ between the groups; interaction p = 0.49, p = 0.10, respectively. Averaged across the 1, 3 and 6-year assessments, there were no significant effects of prenatal ω-3 LCPUFA supplementation on IgE-mediated allergic disease symptoms (adjusted relative risk 0.88 (95% CI 0.69, 1.12), p = 0.29) or sensitization (adjusted relative risk 0.97 (95% CI 0.82, 1.15), p = 0.76). Sensitization patterns to common allergens were consistent with the atopic march, with egg sensitization at 1 year strongly associated with house dust mite sensitization at 6 years, (p < 0.0001).
Discussion
Although there is some evidence to suggest that maternal supplementation with 900mg ω-3 LCPUFA has a protective effect on early symptoms of allergic disease and sensitization in the offspring, we did not observe any differences in the progression of disease over time in this longitudinal analysis. Further investigation into the dose and timing of ω-3 LCPUFA supplementation, including long-term follow up of children using consistent outcome reporting, is essential to determine whether this intervention may be of benefit as a primary prevention strategy for allergic disease.
Conclusion
Maternal supplementation with 900 mg of ω-3 LCPUFA did not change the progression of IgE-mediated allergic disease symptoms or sensitization throughout childhood from 1 to 6 years.
Trial registration
Australian New Zealand Clinical Trials Registry (ACTRN); DOMInO trial ACTRN12605000569606, early childhood allergy follow up ACTRN12610000735055 and 6-year allergy follow up ACTRN12615000498594.
Prenatal Omega-3 reduced infant allergies - 2019
Prenatal Omega-3 Polyunsaturated Fatty Acids and Allergic Risk
Hughes, Megan
Publication: Physician Assistant Institute
Event: Faculty Research Day
Date: 2019-03-29
The prevalence of allergic diseases has increased immensely over the past 2-3 decades, leading to significant decrease in the quality of life in patients who suffer from such disease states. The proposal of certain dietary changes during gestation to enhance the immune system in utero has been brought to light, specifically in the form of omega-3 polyunsaturated fatty acid (n-3 PUFA). This meta-analysis poses to provide a conclusion to if high levels of prenatal n-3 PUFA will have an immunological effect on the fetus thus decreasing their allergic risk later in life.
Download the Poster PDF from VitaminDWiki
14+ VitaminDWiki pages with OMEGA-6 in the title
This list is automatically updated